IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release-Reference-Cited by-同舟云学术

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

Published:2024-08-28 Issue:1 Volume:16 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Schardt John S.¹,Walseng Even¹,Le Kim¹,Yang Chunning¹,Shah Pooja¹,Fu Ying¹,Alam Kausar¹,Kelton Cathryn R.²,Gu Yu¹,Huang Fengying¹,Lin Jia¹,Liu Wenhai¹,Dippel Andrew¹,Zhang Hanzhi¹,Mulgrew Kathy²,Pryts Stacy²,Chennupati Vijaykumar³,Chen Hung-Chang³,Denham Jessica⁴,Chen Xiaoru⁴,Pradhan Pallab⁴,Wu Yuling⁴,Hardman Colin⁵,Zhao Chihao¹,Kierny Michael¹,Song Yang¹,Dovedi Simon J.³,Cemerski Saso²,Mazor Yariv¹

Affiliation:

1. R&D Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA

2. Oncology ICC, AstraZeneca, Gaithersburg, MD, USA

3. Data Science and Advanced Analytics, AstraZeneca, Gaithersburg, MD, USA

4. Oncology ICC, AstraZeneca, Cambridge, UK

5. Discovery Bioanalysis, Clinical Pharmacology & Safety Sciences (CPSS), R&D, AstraZeneca, Gaithersburg, MD, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2024.2395499

Reference72 articles.

1. Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

2. The landscape of bispecific T cell engager in cancer treatment

3. T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions

4. The antibody society. Therapeutic monoclonal antibodies approved or in regulatory review. 2024 Aug 16; www.antibodysociety.org/antibody-therapeutics-product-data.

5. Overcoming the challenges associated with CD3+ T-cell redirection in cancer